Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Smith

Neurological Surgery New York, NY Medical Doctor

NPI 1003979261 CMS profile 45648

645 Madison Ave Fl 34, Frnt 2, New York, NY 10022

Open in the dashboard

General payments

$136,932

203 records reported · program years 2019–2025

Research payments

$3,000

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Smith of New York, NY is reported in the CMS Open Payments database as having received $136,932 across 203 general payments and $3,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58,951 27
2024 General $30,054 27
2024 Research $3,000 5
2023 General $16,926 25
2022 General $13,325 21
2021 General $10,729 49
2020 General $2,719 35
2019 General $4,227 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Smith
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Michael Smith were reported at $58,951. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Michael Smith Neurological Surgery median Middle half National median
2019 $4,227 $582 $138–$3,006 $163
2020 $2,719 $294 $76–$2,174 $114
2021 $10,729 $387 $105–$2,432 $132
2022 $13,325 $542 $139–$2,989 $149
2023 $16,926 $534 $145–$2,697 $160
2024 $30,054 $574 $155–$3,046 $164
2025 $58,951 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $74,879 8 payments
  2. Centinel Spine, LLC $41,526 31 payments
  3. Providence Medical Technology, Inc. $6,764 7 payments
  4. Intrinsic Therapeutics $3,250 2 payments
  5. DePuy Synthes Products, Inc. $2,625 2 payments
  6. 4WEB, Inc. $1,847 16 payments
  7. DePuy Synthes Sales Inc. $1,644 76 payments
  8. Medtronic, Inc. $1,022 20 payments
  9. Globus Medical, Inc. $536 10 payments
  10. NuVasive, Inc. $490 4 payments
  11. Other $2,349 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $128,281 42 payments
  2. Food and Beverage $8,330 158 payments
  3. Travel and Lodging $320 3 payments
Products named General payments · program years 2019–2025
  1. FIBERGRAFT Aeridyan Matrix $65,450 3 payments
  2. PRODISC C SK $34,063 24 payments
  3. PRODISC C VIVO Spine Implant $3,875 3 payments
  4. PRODISC C VIVO Spine Implant $3,250 3 payments
  5. MOUNTAINEER $3,210 3 payments
  6. EXPEDIUM $2,665 5 payments
  7. NAVIGATION $2,625 2 payments
  8. Barricaid Annular Closure Device $2,600 1 payment
  9. SPINE TRUSS SYSTEM $1,847 16 payments
  10. BARRICAID ACD (ANNULAR CLOSURE DEVICE) $650 1 payment
  11. Other $6,693 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Intrinsic Therapeutics $3,000 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

125

Median for Neurosurgery: 83

Drug cost

$1,045

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 62 $455
Diclofenac Sodium Generic 23 $218
Celecoxib Generic 20 $205
Cyclobenzaprine Hcl Generic 20 $167

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$269,388

Medicare's payments for the services billed

Medicare patients

317

Average age 73

Services billed

1,222

178 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 36%
Diabetes 26%
Osteoporosis 26%
Depression 23%
Cancer 16%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record